Know-How | Stago

Clarity Peer Group Program for Stago Customers

Clarity for Stago customers is a fully web based peer group program. Today’s fast paced and hectic diagnostic world demands a product that can quickly identify shifts, trends, and allow for immediate corrective action. Clarity provides all of this and more.

Meet the STA Compact Max “Innovation born from Expertise”.

AACC 2013 - STA Compact Max Launch – July, 28th 2013 Houston, TX, home of NASA’s Mission Control, was the perfect place for the launch of Stago’s new STA Compact Max analyzer. “Houston ALL SYSTEMS ARE GO”, the launch was a total success.

Stago Launches Products for Measurement of Rivaroxaban

July 12, 2012, Parsippany, NJ, USA – The STA®–Rivaroxaban Calibrator and Controls are highly specific, automation-ready products for determining the rivaroxaban concentration in plasma when used in conjunction with the STA®-Liquid Anti-Xa assay. This method was shown to have favorable performance with respect to its linearity and coefficient of variation (CV) in a recent publication.1

Stago Offers Three Factor VII Detection Methods

June 29, 2012, Parsippany, NJ, USA – Diagnostica Stago, Inc. announces products to suit a variety of clinical research needs for factor VII (FVII). Factor VII is a zymogen that upon activation to its active form, factor VIIa (FVIIa) together with Tissue Factor (TF) comprises the first step in the extrinsic pathway of blood coagulation leading to thrombin formation and subsequent formation of the fibrin clot. Fibrin clot formation is critical for normal hemostasis to occur. All the methods below, which utilize citrated plasma, provide researchers with additional tools to investigate FVII biology, structure and function.

Diagnostica Stago Inc. joins AdvaMedDx

April 10, 2012, Parsippany, NJ, USA – Diagnostica Stago, Inc. (DSI) has joined AdvaMedDx, a division of the Advanced Medical Technology Association (AdvaMed) dedicated to addressing the policy and regulatory issues facing in vitro diagnostic companies both in the United States and abroad.

Stago Offers Three Procoagulant Microparticle Detection Methods

January 4, 2012, Parsippany, NJ, USA – Diagnostica Stago announces three new products to suit a variety of clinical research needs for procoagulant and total microparticle detection. Microparticles are tissue factor-bearing phospholipid vesicles that have often been the subject of clinical research studies into various conditions such as cancer, diabetes, sickle cell disorder, as well as parasitic and viral infections. Research into this topic is currently expanding rapidly, with many studies being communicated frequently at scientific meetings.

Stago Establishes Stake in Thrombin Generation Through Acquisition of Thrombinoscope BV

July 1, 2011, Parsippany, NJ, USA – Diagnostica Stago, Inc. (DSI), recently finalized the acquisition of Thrombinoscope BV, based in Maastricht, The Netherlands. This company, researches, develops and markets thrombin generation (TG) systems through the use of the Calibrated Automated Thrombogram® (CAT) system. This system is available for research-only use – and should not be used for diagnostic purposes.

Diagnostica Stago, Inc. Introduces STA-Staclot DRVV Lupus Anticoagulant Assays

October 7, 2010, Parsippany, NJ, USA – Diagnostica Stago, Inc. is pleased to announce the addition of STA-Staclot DRVV Screen and STA Staclot DRVV Confirm lupus anticoagulant (LA) assays. These fully automated assays use the diluted Russell’s viper venom method to detect lupus anticoagulants in patient plasma, and each reagent is bar-coded for ease of use on Stago’s STA analyzers.

Cellquant and Redquant Kits Now Available Exclusively Through Diagnostica Stago

October 1, 2010, Parsippany, NJ, USA – Diagnostica Stago, Inc. (DSI) announces exclusive distribution of the Biocytex Cellquant PNH and Redquant PNH assay kits, previously available through Beckman Coulter. Cellquant and Redquant are no-wash, whole blood, single-color, quantitative, research-use-only flow cytometry assays for analysis of granulocytes and red blood cells, respectively, on samples taken from donors suspected of paroxysmal nocturnal hemoglobinuria (PNH).

Stago’s VASP Assay Used For P2Y12 Biomarker Studies

October 1, 2010, Parsippany, NJ, USA – The VASP flow cytometry assay kit from Diagnostica Stago, Inc. (Stago), examines platelet responsiveness to specific platelet ADP receptor (P2Y12) antagonists and their in vitro effects, and may also be used as a biomarker to track hemostatic effects of P2Y12 inhibitors such as clopidogrel (PLAVIX) and other drugs targeting this receptor. Additionally, as the assay is P2Y12-specific and independent of other platelet receptors, aspirin and abciximab (ReoPro®) do not interfere. Additionally, VASP can be used to perform research on genetic causes of P2Y12 functional deficiency.